Previous Close | 1.2600 |
Open | 1.2500 |
Bid | 1.2600 x 100 |
Ask | 1.3000 x 100 |
Day's Range | 1.2500 - 1.3000 |
52 Week Range | 0.5700 - 1.7000 |
Volume | |
Avg. Volume | 317,411 |
Market Cap | 57.421M |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | 4.74 |
EPS (TTM) | 0.2700 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AVRO
The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.
CAMBRIDGE, Mass. & WATERTOWN, Mass., January 30, 2024--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the "Merger"). Under the terms of the agreement, AVR
Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.